Table 2.
Relative efficacy of ponatinib vs. imatinib—overall survival
| OS | MDACC vs. GRAAPH-2005 | MDACC vs. NCT00038610 | GIMEMA LAL1811 vs. CSI57ADE10 | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | |
| Unadjusted comparison | 0.41 (0.25, 0.68) | < 0.001 | 0.42 (0.24, 0.73)a | 0.002 | 0.40 (0.20, 0.81) | 0.011 |
| 0.36 (0.20, 0.63)b | < 0.001 | |||||
| Population-adjusted comparison | 0.35 (0.17, 0.74) | 0.006 | 0.35 (0.18, 0.70)a | 0.003 | 0.24 (0.09, 0.64) | 0.004 |
| 0.30 (0.15, 0.59)b | 0.001 | |||||
CI confidence interval, HR hazard ratio, OS overall survival
aHR with no censoring on stem cell transplantation
bHR with censoring on stem cell transplantation